Association of CSMD1 with Tumor Mutation Burden and Other Clinical Outcomes in Gastric Cancer
Xuning Wang,1,2,* Shixiang Wang,3,* Yalin Han,1,4 Maolin Xu,1 Peng Li,1 Mu Ke,1 Zhipeng Teng,1 Pu Huang,1 Ziyan Diao,2,5 Yongfeng Yan,1 Qingyu Meng,1 Yanshen Kuang,1 Wei Zheng,1 Hongyi Liu,1 Xuesong Liu,3 Baoqing Jia1 1The Air Force Hospital of Northern Theater PLA, Shenyang, People’...
Guardado en:
| Autores principales: | , , , , , , , , , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Dove Medical Press
2021
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/1af56eeb7b534e208fa176bad5a045fa |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:1af56eeb7b534e208fa176bad5a045fa |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:1af56eeb7b534e208fa176bad5a045fa2021-11-16T18:47:50ZAssociation of CSMD1 with Tumor Mutation Burden and Other Clinical Outcomes in Gastric Cancer1178-7074https://doaj.org/article/1af56eeb7b534e208fa176bad5a045fa2021-11-01T00:00:00Zhttps://www.dovepress.com/association-of-csmd1-with-tumor-mutation-burden-and-other-clinical-out-peer-reviewed-fulltext-article-IJGMhttps://doaj.org/toc/1178-7074Xuning Wang,1,2,* Shixiang Wang,3,* Yalin Han,1,4 Maolin Xu,1 Peng Li,1 Mu Ke,1 Zhipeng Teng,1 Pu Huang,1 Ziyan Diao,2,5 Yongfeng Yan,1 Qingyu Meng,1 Yanshen Kuang,1 Wei Zheng,1 Hongyi Liu,1 Xuesong Liu,3 Baoqing Jia1 1The Air Force Hospital of Northern Theater PLA, Shenyang, People’s Republic of China; 2Department of General Surgery, The First Center of Chinese PLA General Hospital, Beijing, People’s Republic of China; 3School of Life Science and Technology, ShanghaiTech University, Shanghai, People’s Republic of China; 4PLA Rocket Force Characteristic Medical Center, Beijing, People’s Republic of China; 5Chinese PLA Medical School, Beijing, People’s Republic of China*These authors contributed equally to this workCorrespondence: Baoqing JiaDepartment of General Surgery, The First Center of Chinese PLA General Hospital, Beijing, People’s Republic of ChinaEmail baoqingjia@126.comXuesong LiuSchool of Life Science and Technology, ShanghaiTech University, Shanghai, People’s Republic of ChinaEmail liuxs@shanghaitech.edu.cnBackground: Immunotherapy is considered as a powerful and promising clinical approach for the treatment of gastric cancer (GC). However, it is still challenging to precisely screen patients who potentially benefit from immune checkpoint therapy (ICT). Identification of potential biomarkers for selecting patients sensitive to immunotherapy was urgently needed.Methods: Public sequence data and corresponding clinical data were used to explore the potential biomarkers for immunotherapy.Results: We found that CSMD1 is the most frequently mutated gene and its mutation is highly correlated with prognosis in gastric cancer patients. Interestingly, patients with mutated CSMD1 exhibit a high mutation burden and upregulated PDL1 expression. The ratio of microsatellite instability (MSI) in the CSMD1 mutation cohort was higher than that in the cohort without CSMD1 mutation. Furthermore, patients with CSMD1 mutation have been found to possess a higher number of activated CD4+ T cells and neoantigens.Conclusion: CSMD1 mutation may act as a novel biomarker for assessing the survival and immune therapy response in patients with gastric cancer.Keywords: CSMD1, PDL1, tumor mutation burden, gastric cancerWang XWang SHan YXu MLi PKe MTeng ZHuang PDiao ZYan YMeng QKuang YZheng WLiu HLiu XJia BDove Medical Pressarticlecsmd1pdl1tumor mutation burdengastric cancerMedicine (General)R5-920ENInternational Journal of General Medicine, Vol Volume 14, Pp 8293-8299 (2021) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
csmd1 pdl1 tumor mutation burden gastric cancer Medicine (General) R5-920 |
| spellingShingle |
csmd1 pdl1 tumor mutation burden gastric cancer Medicine (General) R5-920 Wang X Wang S Han Y Xu M Li P Ke M Teng Z Huang P Diao Z Yan Y Meng Q Kuang Y Zheng W Liu H Liu X Jia B Association of CSMD1 with Tumor Mutation Burden and Other Clinical Outcomes in Gastric Cancer |
| description |
Xuning Wang,1,2,* Shixiang Wang,3,* Yalin Han,1,4 Maolin Xu,1 Peng Li,1 Mu Ke,1 Zhipeng Teng,1 Pu Huang,1 Ziyan Diao,2,5 Yongfeng Yan,1 Qingyu Meng,1 Yanshen Kuang,1 Wei Zheng,1 Hongyi Liu,1 Xuesong Liu,3 Baoqing Jia1 1The Air Force Hospital of Northern Theater PLA, Shenyang, People’s Republic of China; 2Department of General Surgery, The First Center of Chinese PLA General Hospital, Beijing, People’s Republic of China; 3School of Life Science and Technology, ShanghaiTech University, Shanghai, People’s Republic of China; 4PLA Rocket Force Characteristic Medical Center, Beijing, People’s Republic of China; 5Chinese PLA Medical School, Beijing, People’s Republic of China*These authors contributed equally to this workCorrespondence: Baoqing JiaDepartment of General Surgery, The First Center of Chinese PLA General Hospital, Beijing, People’s Republic of ChinaEmail baoqingjia@126.comXuesong LiuSchool of Life Science and Technology, ShanghaiTech University, Shanghai, People’s Republic of ChinaEmail liuxs@shanghaitech.edu.cnBackground: Immunotherapy is considered as a powerful and promising clinical approach for the treatment of gastric cancer (GC). However, it is still challenging to precisely screen patients who potentially benefit from immune checkpoint therapy (ICT). Identification of potential biomarkers for selecting patients sensitive to immunotherapy was urgently needed.Methods: Public sequence data and corresponding clinical data were used to explore the potential biomarkers for immunotherapy.Results: We found that CSMD1 is the most frequently mutated gene and its mutation is highly correlated with prognosis in gastric cancer patients. Interestingly, patients with mutated CSMD1 exhibit a high mutation burden and upregulated PDL1 expression. The ratio of microsatellite instability (MSI) in the CSMD1 mutation cohort was higher than that in the cohort without CSMD1 mutation. Furthermore, patients with CSMD1 mutation have been found to possess a higher number of activated CD4+ T cells and neoantigens.Conclusion: CSMD1 mutation may act as a novel biomarker for assessing the survival and immune therapy response in patients with gastric cancer.Keywords: CSMD1, PDL1, tumor mutation burden, gastric cancer |
| format |
article |
| author |
Wang X Wang S Han Y Xu M Li P Ke M Teng Z Huang P Diao Z Yan Y Meng Q Kuang Y Zheng W Liu H Liu X Jia B |
| author_facet |
Wang X Wang S Han Y Xu M Li P Ke M Teng Z Huang P Diao Z Yan Y Meng Q Kuang Y Zheng W Liu H Liu X Jia B |
| author_sort |
Wang X |
| title |
Association of CSMD1 with Tumor Mutation Burden and Other Clinical Outcomes in Gastric Cancer |
| title_short |
Association of CSMD1 with Tumor Mutation Burden and Other Clinical Outcomes in Gastric Cancer |
| title_full |
Association of CSMD1 with Tumor Mutation Burden and Other Clinical Outcomes in Gastric Cancer |
| title_fullStr |
Association of CSMD1 with Tumor Mutation Burden and Other Clinical Outcomes in Gastric Cancer |
| title_full_unstemmed |
Association of CSMD1 with Tumor Mutation Burden and Other Clinical Outcomes in Gastric Cancer |
| title_sort |
association of csmd1 with tumor mutation burden and other clinical outcomes in gastric cancer |
| publisher |
Dove Medical Press |
| publishDate |
2021 |
| url |
https://doaj.org/article/1af56eeb7b534e208fa176bad5a045fa |
| work_keys_str_mv |
AT wangx associationofcsmd1withtumormutationburdenandotherclinicaloutcomesingastriccancer AT wangs associationofcsmd1withtumormutationburdenandotherclinicaloutcomesingastriccancer AT hany associationofcsmd1withtumormutationburdenandotherclinicaloutcomesingastriccancer AT xum associationofcsmd1withtumormutationburdenandotherclinicaloutcomesingastriccancer AT lip associationofcsmd1withtumormutationburdenandotherclinicaloutcomesingastriccancer AT kem associationofcsmd1withtumormutationburdenandotherclinicaloutcomesingastriccancer AT tengz associationofcsmd1withtumormutationburdenandotherclinicaloutcomesingastriccancer AT huangp associationofcsmd1withtumormutationburdenandotherclinicaloutcomesingastriccancer AT diaoz associationofcsmd1withtumormutationburdenandotherclinicaloutcomesingastriccancer AT yany associationofcsmd1withtumormutationburdenandotherclinicaloutcomesingastriccancer AT mengq associationofcsmd1withtumormutationburdenandotherclinicaloutcomesingastriccancer AT kuangy associationofcsmd1withtumormutationburdenandotherclinicaloutcomesingastriccancer AT zhengw associationofcsmd1withtumormutationburdenandotherclinicaloutcomesingastriccancer AT liuh associationofcsmd1withtumormutationburdenandotherclinicaloutcomesingastriccancer AT liux associationofcsmd1withtumormutationburdenandotherclinicaloutcomesingastriccancer AT jiab associationofcsmd1withtumormutationburdenandotherclinicaloutcomesingastriccancer |
| _version_ |
1718426222722023424 |